Pharmaceutical Supply – Meclizine Hydrochloride Tablets

The contract involves the supply of Meclizine Hydrochloride Tablets, USP, in bulk quantities to meet the requirements of the Department of Defense through the Medical Supply Chain Pharm FSA. All tablets must comply with United States Pharmacopeia standards, including stringent quality, purity, and potency specifications, and must adhere to defined shelf-life requirements to ensure efficacy and safety throughout distribution and use. Packaging and labeling must conform to regulatory guidelines and be suitable for bulk handling and military logistics, with final delivery mandated to Fort Bragg, North Carolina. The solicitation is issued as a subcontract under NAICS code 325412, which classifies pharmaceutical preparation manufacturing, and is open for responses until August 3, 2026. The procurement is part of the Department of Defense’s broader pharmaceutical supply chain operations, aimed at maintaining adequate stockpiles of essential medications for military healthcare facilities. While the specific volume and unit pricing are not detailed, bidders must demonstrate capability to fulfill large-scale delivery schedules with full regulatory compliance, accurate documentation, and timely shipment to the designated military location without disruption.